Ex-FDA/CMS chief: Delivery efficiencies could balance drug costs
This article was originally published in Scrip
Executive Summary
There have been few forums held in Washington in the past year about the biopharmaceutical industry that haven’t had at least one discussion focused on high drug prices, with Gilead Sciences $1,000-per-pill hepatitis C virus (HCV) drug Sovaldi (sofosbuvir) generally at the center of the debate.